Cellseed Inc. · TSE:7776
Cellseed — FY2023 Earnings Presentation
29 slides from Cellseed's earnings presentation, Feb 26, 2024
Slide 1: CellSeed Inc. Fiscal 2023 Earnings Results Presentation
CellSeed Inc. Fiscal 2023 Earnings Results Presentation Tokyo Stock Exchange Growth Code:7776
Slide 2: Contents
Contents Company Profile Financial Summary of Fiscal Year Ending December 31, 2023 Progress of each business © 2024 CellSeed Inc. 1
Slide 3: Head office, CPC, development and manufacturing facility
Head office・CPC・development and manufacturing facility Established May, 2001 Core competence Cell Sheet Engineering based on Temperature Responsive Polymers Listed Tokyo Stock Exchange Growth（7776) Head Office Telecom Center 15F (East Wing) Telecom Center Building 2-5-10, Aomi, Koto-ku, Tokyo Cell P
Slide 4: CellSeed Inc. Corporate Information
CellSeed Inc. Corporate Information Mission We take the initiative of contributing to global health care in the valuable and innovative field of regenerative medicine. Regenerative Medical Regenerative Medicine Products Business Supporting Business Commercialization of Cell Sheet Therapies Intellige
Slide 5: Our Business Model
Our Business Model Medical Hospitals Seeds Products Patients Treatment University Base of Innovation Collaborative Fee Medical Research Expenses Business Alliance Partner Companies Delivering the technology developed at a university and developed at a venture to patients as soon as possible. © 2024
Slide 6: Development of Treatment Using Cell Sheet Engineering
Development of Treatment Using Cell Sheet Engineering © 2024 CellSeed Inc. 5
Slide 7: Contents
Contents Company Profile Financial Summary of Fiscal Year Ending December 31, 2023 Progress of each business © 2024 CellSeed Inc. 6
Slide 8: Year financial summary FY 12/2023
Year financial summary FY 12/2023 First Half of the FY2023 First Half of the FY2022 (January 2023 - Dec 2023) (January 2022 - Dec 2022) Change from Change from Amount Amount Previous Period Previous Period (Millions of yen) (Millions of yen) (Millions of yen) (%) Sales 190 63 50.4 126 Operating prof
Slide 9: Topics on financial results in the term ended December 2023
Topics on financial results in the term ended December 2023 Cell cultureware business In particular, overseas sales grew considerably. Achieved record-high sales. Commissioned regenerative medicine business Tokai University entrusted us with the production of autologous cartilage cell sheets f
Slide 10: The 24th issuance of share acquisition rights to a third party
The 24th issuance of share acquisition rights (with a provision for revising exercise price) for allocation of shares to a third party Allocation date June 5, 2023 Number of share acquisition rights to 69,000 be issued Allocatee Barclays Bank Assumed procurement 2,362,601,000 yen (roughly estimated
Slide 11: Contents
Contents Company Profile Financial Summary of Fiscal Year Ending December 31, 2023 Progress of each business © 2024 CellSeed Inc. 10
Slide 12: CellSeed Temperature Sensitive Cell Cultureware Lineup
CellSeed Temperature Sensitive Cell Cultureware Lineup UpCell® RepCell® This cultureware In addition to the same maintains the characteristics as those physiological activity of of UpCell®, this cells and retains a high cultureware allows for level of antigen proteins the recovery of cells in a on t
Slide 13: Variation in sales of the cell cultureware business
Variation in sales of the cell cultureware business Threefold sales growth in 7 years! 2016 2017 2018 2019 2020 2021 2022 2023 Achieved record-high sales © 2024 CellSeed Inc. 12
Slide 14: Start of sale: VIVANT-CELL Pot with UpCell Plate
Start of sale On February 15, 2024, we released the new product VIVANT-CELL Pot with UpCell Plate. Highly functional stem cells can be fractionated easily with VIVANT-CELL Pot. Intact cells can be collected with UpCell Plate. © 2024 CellSeed Inc. 13
Slide 15: Cultivation of new markets for cell cultureware
Cultivation of new markets for cell cultureware Need for technology to culture cells in large quantities Possibility of Biopharmaceutical manufacturing Manufacturing cells for use in immunotherapy market expansion Development of cellular foods such as cultured meat Required number of cells Cul
Slide 16: Regenerative medicine supporting business: consignment services
Regenerative medicine supporting business: Regenerative medicine consignment services Regenerative Medicine Promotion Act Advanced medical care Acquisition of licenses for manufacturing and sale in accordance with the Act on R&D in academia Pharmaceuticals and Medical Devices. Fundamental Clinical N
Slide 17: Regenerative medicine consignment services: bridge to patients
Regenerative medicine supporting business: Regenerative medicine consignment services Serving as a bridge to deliver regenerative medicine to patients by solving problems with academia and closing the gap Acquisition of licenses for manufacturing and sale in accordance with the Act on R&D in academi
Slide 18: Regenerative Medicine Supporting Business
Regenerative Medicine Supporting Business Development of Manufacturing Methods and 1 Contract Manufacturing for Cell Sheet Products Development of cell sheet manufacturing methods Contract manufacturing of cell sheet products Quality testing of cell sheets, etc. Facility Management and Applica
Slide 19: Commissioned projects in our regenerative medicine service
Commissioned projects in our regenerative medicine service For the regenerative medicine service, we obtained the permission to manufacture specific processed cells (facility No. FA3160008) in March 2017 and the permission to manufacture products for regenerative medicine in October 2018 and have un
Slide 20: Pipeline Progress
Pipeline Progress Regenerative medicine The Act on the Safety of The Act on Pharmaceuticals Regenerative Medicine and Medical Devices Self-funded Manufacturing Clinical Advanced and sales medical research medical dare treatment Clinical trials Fundamental Clinical Application Pipeline Sales research
Slide 21: Knee Osteoarthritis (OA)
Knee Osteoarthritis (OA) Prevalence increases with age 1.5 to 2 times more women than men 30 million 10 million patients Number of patients is expected potential patients with symptoms to increase due to aging of the （Japan） （Japan） population No fundamental medical therapy for OA © 2024 CellS
Slide 22: Allogeneic chondrocyte sheet
Allogeneic chondrocyte sheet Prof. Masato Sato Good results in all 10 cases in clinical research technology transfer Developed as a regenerative medicine product Allogeneic chondrocyte sheets © 2024 CellSeed Inc. 21
Slide 23: Process of producing allogeneic cartilage cell sheets (CLS2901C)
Process of producing allogeneic cartilage cell sheets (CLS2901C） Cell Bank An extra finger excised from a Frozen Isolated Amplified patient with Semination storage cartilage culture polydactyly P0 P1 Cell Stock （Master Cell Bank） PX Working Cell Bank Safety Safety Safety Cell Sheets Implantation Pre
Slide 24: Safety testing of cell banks and cell sheets
Safety testing of cell banks and cell sheets Cell number, Cell viability, Sterility test, Endotoxins test, Cell Bank Virus test, Mycoplasma test, and so on An extra finger excised from a Frozen Isolated Amplified patient with Semination storage cartilage culture polydactyly P0 P1 Cell Stock （Master
Slide 25: The Master Cell Bank for Clinical Trials is Established
Safety testing of cell banks and cell sheets Cell number, Cell viability, Sterility test, Endotoxins test, Cell Bank Virus test, Mycoplasma test, and so on An extra finger excised from a Frozen Isolated Amplified patient with Semination storage cartilage culture polydactyly P0 P1 Cell Stock P1 Cell
Slide 26: Phase-3 test for allogeneic cartilage cell sheets
Phase-3 test for allogeneic cartilage cell sheets Test design: Multicenter, single-blinded, randomized, parallel-group trial Target number of 96 cases: Subjects: Patients with knee osteoarthritis subject to low tibial osteotomy Major items to be Patients’ reports (evaluation method in which patients
Slide 27: 3rd Cell Sheet Engineering Innovation Forum Lecturers
3rd Cell Sheet Engineering Innovation Forum Date :Friday, Nov. 24, 2023 Venue :Miraikan Hall on the 7th floor of the National Museum of Emerging Science and Innovation, etc. Lecturers Prof. Masato Sato (Professor of Department of Orthopaedics, School of Medicine, Tokai University） Prof. Haruko Takey
Slide 28: Scenes from 3rd Cell Sheet Engineering Innovation Forum
Scenes from 3rd Cell Sheet Engineering Innovation Forum The 4th Cell Sheet Engineering Innovation Forum will be held in 2025 © 2024 CellSeed Inc. 27
Slide 29: Disclaimer
This presentation is made by CellSeed Inc. solely for the disclosure of the financial statements, and not published for the purpose of soliciting sales or purchases of securities in Japan and any other regions. Copyright © CellSeed Inc. All Rights Reserved.